Seres Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Author's Avatar
Jun 09, 2023

Seres Therapeutics, Inc. (Nasdaq: MCRB) (“Seres” or the “Company”), a leading microbiome therapeutics company, today announced that on June 7, 2023, the Compensation and Talent Committee of Seres’ board of directors granted inducement equity grants covering an aggregate of 19,400 shares of its common stock to six new employees, consisting of stock options to purchase an aggregate of 9,700 shares of common stock and restricted stock units (“RSUs”), covering an aggregate of 9,700 shares of its common stock.